| Bioactivity | Verucerfont is a corticotropin-releasing factor receptor 1 (CRF1) antagonist with IC50s of ~6.1, >1000 and >1000 nM for CRF1, CRF2, and CRF-BP, respectively. | ||||||||||||
| Target | IC50: 6.1 nM (CRF1), >1000 nM (CRF2), >1000 nM (CRF-BP) | ||||||||||||
| In Vivo | Post hoc analysis shows that the prototypic non-peptide CRF1 receptor antagonist NBI30775 (R121919) and Verucerfont are both significantly different from vehicle, CP-316 311, and pexacerfont (PPost hoc analysis shows that both NBI30775 and Verucerfont inhibit ACTH release throughout the following 6 h of measurement (P<0.001 vs vehicle at each time-point, and vs the respective pretreatment baseline)[1]. | ||||||||||||
| Name | Verucerfont | ||||||||||||
| CAS | 885220-61-1 | ||||||||||||
| Formula | C22H26N6O2 | ||||||||||||
| Molar Mass | 406.48 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Schwandt ML, et al. The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects. Neuropsychopharmacology. 2016 Nov;41(12):2818-2829. |
Verucerfont
CAS: 885220-61-1 F: C22H26N6O2 W: 406.48
Verucerfont is a corticotropin-releasing factor receptor 1 (CRF1) antagonist with IC50s of ~6.1, >1000 and >1000 nM for
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.